|
CN1087725C
(zh)
|
1994-03-25 |
2002-07-17 |
同位素技术有限公司 |
用氘代方法增强药物效果
|
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
DK0825186T3
(da)
|
1996-08-16 |
2002-07-22 |
Pfizer |
2-aminobenzazepinderivater og deres anvendelse til behandling af immunosuppression
|
|
US20040141983A1
(en)
|
1999-03-15 |
2004-07-22 |
Protein Design Labs, Inc. |
Compositions against cancer antigen LIV-1 and uses thereof
|
|
US20110214206A1
(en)
|
1999-05-06 |
2011-09-01 |
La Rosa Thomas J |
Nucleic acid molecules and other molecules associated with plants
|
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
US20060142202A1
(en)
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
GB0118155D0
(en)
|
2001-07-25 |
2001-09-19 |
Lorantis Ltd |
Superantigen
|
|
JP2005519990A
(ja)
|
2001-10-12 |
2005-07-07 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
|
|
US6942972B2
(en)
|
2001-10-24 |
2005-09-13 |
Beckman Coulter, Inc. |
Efficient synthesis of protein-oligonucleotide conjugates
|
|
TW200303759A
(en)
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
|
US6953787B2
(en)
|
2002-04-12 |
2005-10-11 |
Arena Pharmaceuticals, Inc. |
5HT2C receptor modulators
|
|
NZ538812A
(en)
|
2002-08-15 |
2009-02-28 |
3M Innovative Properties Co |
Immunostimulatory compositions and methods of stimulating an immune response
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
AU2003300184B8
(en)
|
2002-12-30 |
2009-12-03 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
|
CN1798575A
(zh)
|
2003-04-04 |
2006-07-05 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
|
AU2004244962A1
(en)
|
2003-04-10 |
2004-12-16 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds using metal-containing particulate support materials
|
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
WO2005065678A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Immunomodulatory combinations
|
|
US7585326B2
(en)
|
2004-08-06 |
2009-09-08 |
Spinalmotion, Inc. |
Methods and apparatus for intervertebral disc prosthesis insertion
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
EP1809671B1
(en)
|
2004-11-09 |
2014-07-16 |
University Of Southern California |
CpG/antibody conjugate against cancer
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
TWI404537B
(zh)
|
2005-08-19 |
2013-08-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
AU2006301492B2
(en)
|
2005-10-11 |
2011-06-09 |
Amgen Research (Munich) Gmbh |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
|
US20090074711A1
(en)
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
|
US7614279B2
(en)
|
2006-10-10 |
2009-11-10 |
Porous Materials, Inc. |
Determination of pore structure characteristics of filtration cartridges as a function of cartridge length
|
|
CA2666667C
(en)
|
2006-10-19 |
2023-06-20 |
Baylor College Of Medicine |
Generating an immune response by inducing cd40 and pattern recognition receptors
|
|
HRP20140049T1
(hr)
|
2007-01-05 |
2014-02-28 |
University Of Zürich |
Anti beta-amiloid antitijela i njihova upotreba
|
|
KR20120017469A
(ko)
|
2007-01-05 |
2012-02-28 |
유니버시티 오브 취리히 |
질환 특이적 결합 분자 및 표적을 제공하는 방법
|
|
ES2552471T3
(es)
|
2007-02-07 |
2015-11-30 |
The Regents Of The University Of California |
Conjugados de agonistas de TLR sintéticos y usos de los mismos
|
|
CA2691444C
(en)
|
2007-06-29 |
2016-06-14 |
Gilead Sciences, Inc. |
Purine derivatives and their use as modulators of toll-like receptor 7
|
|
RU2010107199A
(ru)
|
2007-07-31 |
2011-09-10 |
Дзе Джонс Хопкинс Юниверсити (Us) |
Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
|
|
NZ599777A
(en)
|
2007-11-07 |
2013-09-27 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
WO2010014913A1
(en)
|
2008-08-01 |
2010-02-04 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
|
ES2467108T3
(es)
|
2008-12-09 |
2014-06-11 |
Gilead Sciences, Inc. |
Moduladores de receptores tipo toll
|
|
US20110301056A1
(en)
*
|
2008-12-12 |
2011-12-08 |
Oncotherapy Science, Inc. |
Nectin-4 for target genes of cancer therapy and diagnosis
|
|
KR20110117705A
(ko)
|
2009-02-11 |
2011-10-27 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
톨-유사 수용체 조정제 및 질병의 치료
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US20120121580A1
(en)
|
2009-07-28 |
2012-05-17 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
CA2771609C
(en)
|
2009-08-18 |
2018-10-02 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
EP2467380B1
(en)
|
2009-08-18 |
2016-11-30 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
US8962652B2
(en)
|
2009-10-22 |
2015-02-24 |
Gilead Sciences, Inc. |
Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
BR112012021576A2
(pt)
|
2010-02-26 |
2016-10-25 |
Novo Nordisk As |
composições estáveis contendo anticorpo.
|
|
PT2552959T
(pt)
|
2010-03-26 |
2017-04-21 |
Memorial Sloan Kettering Cancer Center |
Anticorpos para muc16 e métodos de utilização dos mesmos
|
|
AU2011239569B2
(en)
|
2010-04-16 |
2014-07-24 |
Baylor College Of Medicine |
Method for treating solid tumors
|
|
MX2012012833A
(es)
|
2010-05-07 |
2012-11-30 |
Baylor Res Inst |
Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir).
|
|
RU2012153786A
(ru)
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
BR112013002940A2
(pt)
|
2010-08-13 |
2019-09-24 |
Baylor Res Institute |
adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
|
|
EP3409287B9
(en)
|
2010-09-29 |
2021-07-21 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 191p4d12 proteins
|
|
JP5951615B2
(ja)
|
2010-10-01 |
2016-07-13 |
ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｔｌｒアゴニストの治療用途および組み合わせ治療
|
|
US20120082658A1
(en)
|
2010-10-01 |
2012-04-05 |
Ventirx Pharmaceuticals, Inc. |
Methods for the Treatment of Allergic Diseases
|
|
JP6105481B2
(ja)
|
2010-12-06 |
2017-03-29 |
シアトル ジェネティクス，インコーポレーテッド |
Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用
|
|
DE102010062835A1
(de)
|
2010-12-10 |
2012-06-14 |
Codewrights Gmbh |
Verfahren zur Erstellung eines kundenspezifischen Setups für eine Bibliothek von Gerätetreibern
|
|
KR101614997B1
(ko)
|
2011-01-10 |
2016-04-22 |
씨티 아틀란틱 엘티디. |
종양 관련 항원 결합 항체를 포함하는 조합 요법
|
|
CN103562201B
(zh)
|
2011-01-12 |
2016-10-19 |
帆德制药股份有限公司 |
作为toll样受体调节剂的取代的苯并氮杂卓
|
|
DK2663550T3
(en)
|
2011-01-12 |
2017-03-27 |
Ventirx Pharmaceuticals Inc |
SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
|
|
TW201247706A
(en)
|
2011-03-08 |
2012-12-01 |
Baylor Res Inst |
Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
|
|
HUE055286T2
(hu)
|
2011-04-08 |
2021-11-29 |
Janssen Sciences Ireland Unlimited Co |
Pirimidinszármazékok vírusfertõzések kezelésére
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
SG194852A1
(en)
|
2011-05-18 |
2013-12-30 |
Janssen R & D Ireland |
Quinazoline derivatives for the treatment of viral infections and further diseases
|
|
BR112014004168A2
(pt)
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
AU2012328917B2
(en)
|
2011-10-24 |
2017-05-25 |
Abbvie Inc. |
Bispecific immunobinders directed against TNF and IL-17
|
|
US20140302511A1
(en)
|
2011-10-28 |
2014-10-09 |
Pharmalogicals Research Pte. Ltd. |
Cancer stem cell-specific molecule
|
|
WO2013096744A1
(en)
|
2011-12-21 |
2013-06-27 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
|
WO2013096835A1
(en)
|
2011-12-23 |
2013-06-27 |
Abbvie Inc. |
Stable protein formulations
|
|
GB201122325D0
(en)
|
2011-12-23 |
2012-02-01 |
Cytoguide As |
Novel formulations
|
|
DK2812331T3
(en)
|
2012-02-08 |
2019-04-08 |
Janssen Sciences Ireland Unlimited Co |
PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
|
|
PE20190658A1
(es)
|
2012-02-24 |
2019-05-08 |
Abbvie Stemcentrx Llc |
Moduladores y metodos de empleo novedosos
|
|
US9556167B2
(en)
|
2012-05-02 |
2017-01-31 |
Yale University |
TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
|
|
AU2013255511B2
(en)
|
2012-05-04 |
2016-01-28 |
Pfizer Inc. |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
NZ701915A
(en)
|
2012-05-18 |
2016-11-25 |
Genentech Inc |
High-concentration monoclonal antibody formulations
|
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
|
LT3495387T
(lt)
|
2012-07-13 |
2021-11-25 |
Roche Glycart Ag |
Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
CN104781239B
(zh)
|
2012-08-10 |
2019-03-01 |
爱尔兰詹森科学公司 |
用于治疗病毒感染和另外的疾病的烷基嘧啶衍生物
|
|
WO2014052828A1
(en)
|
2012-09-27 |
2014-04-03 |
The Regents Of The University Of California |
Compositions and methods for modulating tlr4
|
|
LT2906563T
(lt)
|
2012-10-10 |
2018-06-11 |
Janssen Sciences Ireland Uc |
Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui
|
|
EP2925729B1
(en)
|
2012-11-16 |
2017-10-18 |
Janssen Sciences Ireland UC |
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
|
|
PL2931738T3
(pl)
|
2012-12-13 |
2019-07-31 |
Aduro Biotech, Inc. |
Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania
|
|
US20140187501A1
(en)
|
2012-12-28 |
2014-07-03 |
Blend Therapeutics, Inc. |
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
|
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
|
JP6636803B2
(ja)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Ｂｃｍａに対する抗体の選択のための方法
|
|
WO2014124258A2
(en)
*
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
WO2014128189A1
(en)
|
2013-02-21 |
2014-08-28 |
Janssen R&D Ireland |
2-aminopyrimidine derivatives for the treatment of viral infections
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
US10549082B2
(en)
|
2013-04-17 |
2020-02-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for cancer treatment
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
KR102322425B1
(ko)
|
2013-07-30 |
2021-11-05 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
|
|
AU2014312215B2
(en)
|
2013-08-28 |
2020-02-27 |
Abbvie Stemcentrx Llc |
Site-specific antibody conjugation methods and compositions
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
BR112016015140A2
(pt)
|
2013-12-30 |
2018-01-23 |
Epimab Biotherapeutics Inc. |
imunoglobulina com fabs in-tandem e usos das mesmas
|
|
CN105899539B
(zh)
|
2014-01-10 |
2021-11-09 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
|
US10421971B2
(en)
|
2014-01-15 |
2019-09-24 |
The University Of Chicago |
Anti-tumor therapy
|
|
KR20160106170A
(ko)
|
2014-01-22 |
2016-09-09 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항체 및 항체-부하된 수지상 세포 매개된 요법을 위한 방법 및 조성물
|
|
MX377916B
(es)
|
2014-04-22 |
2025-03-10 |
Hoffmann La Roche |
Compuestos 4-amino-imidazoquinolina.
|
|
BR112016024363A2
(pt)
|
2014-04-25 |
2017-10-10 |
Pf Medicament |
conjugado de anticorpo-fármaco e seu uso para tratamento de câncer
|
|
EP3166976B2
(en)
|
2014-07-09 |
2026-04-08 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
US20160015803A1
(en)
|
2014-07-18 |
2016-01-21 |
Ross Kedl |
Immunostimulatory combinations and use thereof
|
|
WO2016016299A1
(en)
|
2014-07-29 |
2016-02-04 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
JP6464255B2
(ja)
|
2014-08-04 |
2019-02-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
MX2017003123A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
CA2960436C
(en)
|
2014-09-16 |
2021-01-05 |
Gilead Sciences, Inc. |
Solid forms of a toll-like receptor modulator
|
|
WO2016064899A1
(en)
|
2014-10-21 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
|
WO2016075670A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
|
WO2016100302A2
(en)
|
2014-12-16 |
2016-06-23 |
Celgene Corporation |
Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
|
|
EP3546473B1
(en)
|
2014-12-16 |
2025-12-10 |
Kayla Therapeutics |
Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
|
|
EP3233835B1
(en)
|
2014-12-18 |
2019-01-23 |
F.Hoffmann-La Roche Ag |
Benzazepine sulfonamide compounds
|
|
JP6676058B2
(ja)
|
2015-01-14 |
2020-04-08 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
MA41645A
(fr)
|
2015-03-04 |
2018-01-09 |
Abbvie Stemcentrx Llc |
Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
|
|
KR102581546B1
(ko)
|
2015-03-06 |
2023-09-25 |
에프. 호프만-라 로슈 아게 |
벤즈아제핀 다이카복스아미드 화합물
|
|
US9943416B2
(en)
|
2015-03-10 |
2018-04-17 |
Simplify Medical Pty Limited |
Intervertebral spacer that dynamically promotes bone growth
|
|
EP3328377A4
(en)
|
2015-07-31 |
2019-03-13 |
Tarveda Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
|
|
CA2994965A1
(en)
|
2015-08-06 |
2017-02-09 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for tumor therapy
|
|
CR20180101A
(es)
|
2015-08-13 |
2018-04-12 |
Merck Sharp & Dohme |
Compuestos di-nucleóticos cíclicos como agonistas de sting
|
|
HK1257270A1
(zh)
|
2015-09-15 |
2019-10-18 |
Gilead Sciences, Inc. |
用於治疗hiv的toll样受体(tlr)调节剂
|
|
CN108055842B
(zh)
|
2015-09-17 |
2021-06-29 |
豪夫迈·罗氏有限公司 |
亚磺酰基苯基或磺亚胺酰基苯基苯并氮杂䓬
|
|
CA2994858C
(en)
*
|
2015-09-25 |
2024-01-23 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
|
EP3356410B1
(en)
|
2015-10-02 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
EP3356407B1
(en)
|
2015-10-02 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
TN2018000112A1
(en)
|
2015-10-29 |
2019-10-04 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
PT3380525T
(pt)
|
2015-11-25 |
2024-02-05 |
Immunogen Inc |
Formulações farmacêuticas e métodos que as utilizam
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
|
EP3386536A4
(en)
|
2015-12-07 |
2019-07-31 |
Opi Vi- IP Holdco LLC |
COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF
|
|
WO2017117269A1
(en)
|
2015-12-29 |
2017-07-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for dectin-2 stimulation and cancer immunotherapy
|
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
WO2017123657A1
(en)
|
2016-01-11 |
2017-07-20 |
Gary Glick |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
|
RS67188B1
(sr)
|
2016-01-11 |
2025-10-31 |
Innate Tumor Immunity Inc |
Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer
|
|
CN115969970A
(zh)
|
2016-02-10 |
2023-04-18 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan的组合
|
|
US20190048094A1
(en)
|
2016-02-24 |
2019-02-14 |
Oncomed Pharmaceuticals, Inc. |
Redirecting immune responses
|
|
SG10201912074PA
(en)
|
2016-03-18 |
2020-02-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
WO2017172981A2
(en)
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
CA3018253A1
(en)
|
2016-03-31 |
2017-10-05 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
US9944573B2
(en)
|
2016-04-13 |
2018-04-17 |
Siluria Technologies, Inc. |
Oxidative coupling of methane for olefin production
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
AU2017259654B2
(en)
|
2016-05-06 |
2020-02-27 |
Shanghai De Novo Pharmatech Co., Ltd. |
Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
|
|
JP6918838B2
(ja)
|
2016-05-23 |
2021-08-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
|
|
EP3464274B1
(en)
|
2016-05-23 |
2020-05-27 |
H. Hoffnabb-La Roche Ag |
Benzazepine dicarboxamide compounds with secondary amide function
|
|
BR112018074453A2
(pt)
|
2016-05-27 |
2019-03-19 |
Abbvie Biotherapeutics Inc. |
proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
|
|
JP7012668B2
(ja)
|
2016-06-12 |
2022-02-14 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
|
|
CN109476749A
(zh)
|
2016-06-30 |
2019-03-15 |
豪夫迈·罗氏有限公司 |
改良的过继性t细胞疗法
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
KR102726248B1
(ko)
|
2016-07-07 |
2024-11-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항체-애쥬번트 접합체
|
|
AU2017320742B2
(en)
|
2016-08-29 |
2021-08-05 |
F. Hoffmann-La Roche Ag |
7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
|
|
CN109803679A
(zh)
|
2016-08-30 |
2019-05-24 |
得克萨斯州大学系统董事会 |
在基因组重新编码生物体中生产硒代生物制剂
|
|
US20190345191A1
(en)
|
2016-08-31 |
2019-11-14 |
Innate Tumor Immunity, Inc. |
Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
|
|
CN109923106B
(zh)
|
2016-09-02 |
2022-09-13 |
吉利德科学公司 |
toll样受体调节剂化合物
|
|
EP3507288B1
(en)
|
2016-09-02 |
2020-08-26 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
EP3523314A1
(de)
|
2016-10-07 |
2019-08-14 |
Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH |
Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
|
|
JOP20170188A1
(ar)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
WO2018100558A2
(en)
|
2016-12-01 |
2018-06-07 |
Takeda Pharmaceutical Company Limited |
Cyclic dinucleotide
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
CN110290810A
(zh)
|
2016-12-13 |
2019-09-27 |
博尔特生物治疗药物有限公司 |
抗体佐剂缀合物
|
|
WO2018119118A1
(en)
|
2016-12-20 |
2018-06-28 |
Oncomed Pharmaceuticals, Inc. |
Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
|
|
SG11201905622VA
(en)
|
2017-01-17 |
2019-08-27 |
Genentech Inc |
Subcutaneous her2 antibody formulations
|
|
US11492367B2
(en)
|
2017-01-27 |
2022-11-08 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
WO2018140831A2
(en)
*
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
CA3049842A1
(en)
|
2017-02-02 |
2018-08-09 |
Silverback Therapeutics, Inc. |
Construct-peptide compositions and methods of use thereof
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
CA3053568A1
(en)
|
2017-02-21 |
2018-08-30 |
Board Of Regents, The University Of Texas System |
Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
|
|
US11274160B2
(en)
|
2017-03-02 |
2022-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to Nectin-4 and uses thereof
|
|
ES2894731T3
(es)
|
2017-03-15 |
2022-02-15 |
Silverback Therapeutics Inc |
Compuestos de benzazepina, conjugados y usos de los mismos
|
|
DK3609540T5
(da)
|
2017-04-14 |
2024-09-02 |
Bolt Biotherapeutics Inc |
Fremgangsmåde til immunkonjugatsyntese
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
CN111675761B
(zh)
|
2017-06-05 |
2023-10-20 |
艾更斯司股份有限公司 |
柄蛋白-4结合蛋白及其使用方法
|
|
EP3634401A1
(en)
|
2017-06-07 |
2020-04-15 |
Silverback Therapeutics, Inc. |
Antibody construct conjugates
|
|
EP3634485A4
(en)
|
2017-06-07 |
2021-07-21 |
Silverback Therapeutics, Inc. |
CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
|
|
SG11201912010XA
(en)
|
2017-06-12 |
2020-01-30 |
Obsidian Therapeutics Inc |
Pde5 compositions and methods for immunotherapy
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
MX2020004185A
(es)
|
2017-09-27 |
2021-01-08 |
Univ Southern California |
Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva.
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
EP3710059A1
(en)
|
2017-11-14 |
2020-09-23 |
Dynavax Technologies Corporation |
Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
|
|
WO2019118884A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
KR20200103040A
(ko)
|
2017-12-21 |
2020-09-01 |
다이닛본 스미토모 세이야꾸 가부시끼가이샤 |
Tlr7 아고니스트를 포함하는 병용 약물
|
|
KR102892725B1
(ko)
|
2018-05-09 |
2025-12-01 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
인간 넥틴4에 특이적인 항체
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
KR20210053924A
(ko)
|
2018-08-29 |
2021-05-12 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
Egfr을 표적으로 하는 면역접합체
|
|
JP2022500413A
(ja)
|
2018-09-12 |
2022-01-04 |
シルバーバック セラピューティックス インコーポレイテッド |
Ｔｏｌｌ様受容体アゴニストの抗体コンジュゲート
|
|
US20200113912A1
(en)
|
2018-09-12 |
2020-04-16 |
Silverback Therapeutics, Inc. |
Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
|
|
WO2020056194A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
|
AU2019337654A1
(en)
|
2018-09-12 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Substituted benzazepine compounds, conjugates, and uses thereof
|
|
CA3125302A1
(en)
|
2019-01-18 |
2020-07-23 |
University Of Southern California |
Methods and compositions to improve the safety and efficacy of cellular therapies
|
|
AU2020241686A1
(en)
|
2019-03-15 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting HER2
|
|
WO2020190734A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting pd-l1
|
|
US20220226492A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting HER2
|
|
US20220152215A1
(en)
|
2019-03-15 |
2022-05-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting CEA
|
|
WO2020190762A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported tlr agonists
|
|
AU2020291014B2
(en)
|
2019-06-13 |
2025-06-05 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
WO2020252254A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported aminobenzazepine compounds
|
|
MX2021015533A
(es)
|
2019-06-19 |
2022-02-10 |
Silverback Therapeutics Inc |
Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
|
|
WO2021007428A2
(en)
*
|
2019-07-09 |
2021-01-14 |
The Johns Hopkins University |
Molecules, compositions and methods for treatment of cancer
|
|
US20210139477A1
(en)
|
2019-07-16 |
2021-05-13 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
|
WO2021030665A1
(en)
*
|
2019-08-15 |
2021-02-18 |
Silverback Therapeutics, Inc. |
Formulations of benzazepine conjugates and uses thereof
|
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|